Screener
Vor Biopharma VOR Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Vor Biopharma’s reported figures.
Based on the most recent quarter.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
FAQ
- What is Vor Biopharma's debt-to-equity?
- Vor Biopharma (VOR) reported debt-to-equity of 0.5× in Q1 2025.
- How has Vor Biopharma's debt-to-equity changed year-over-year?
- Vor Biopharma's debt-to-equity increased by 65.0% year-over-year, from 0.3× to 0.5×.
- What is the long-term trend for Vor Biopharma's debt-to-equity?
- Over 2 years (2021 to 2023), Vor Biopharma's debt-to-equity has grown at a 68.5% compound annual growth rate (CAGR), from 0.1× to 0.2×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Vor Biopharma's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude